Publications by authors named "Oliver Gassmann"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

7,386

Total Likes

999

Extended Reach

154,063

Social Features

11
C
Changing R&D models in research-based pharmaceutical companies.
Alexander Schuhmacher, Oliver Gassmann, Markus Hinder

J Transl Med· April 2016

Videos about Article: user user

2 9 4 26

View All Article and Social Media Activity
T
The R&D productivity challenge: transforming the pharmaceutical ecosystem.
Alexander Schuhmacher, Oliver Gassmann, Sebastian Kwisda, Malte Kremer, Markus Hinder

Drug Discov Today· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does pharma R&D need a strategic reset? Adapting to a changing US landscape.
Sebastian Kwisda, Malte Kremer, Niels Sievertsen, Oliver Gassmann, Dominik Hartl

Drug Discov Today· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006-2022)" [Drug Discov. Today 30(2) (2025) 104291].
Alexander Schuhmacher, Markus Hinder, Elazar Brief, Oliver Gassmann, Dominik Hartl

Drug Discov Today· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A case study assessing the impact of M&A and licensing on FDA drug approvals of leading pharmaceutical companies.
Alexander Schuhmacher, Kyrylo Grinchenko, Oliver Gassmann, Dominik Hartl, Markus Hinder

Drug Discov Today· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006-2022).
Alexander Schuhmacher, Markus Hinder, Elazar Brief, Oliver Gassmann, Dominik Hartl

Drug Discov Today· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative analysis of FDA approvals by top 20 pharma companies (2014-2023).
Alexander Schuhmacher, Oliver Gassmann, Markus Hinder, Dominik Hartl

Drug Discov Today· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is the blockbuster imperative broken?
Alexander Schuhmacher, Markus Hinder, Nikolaj Boger, Oliver Gassmann, Dominik Hartl

Drug Discov Today· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigating the origins of recent pharmaceutical innovation.
Alexander Schuhmacher, Markus Hinder, Alexander Dodel, Oliver Gassmann, Dominik Hartl

Nat Rev Drug Discov· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of pharma R&D productivity - a new perspective needed.
Alexander Schuhmacher, Markus Hinder, Alexander von Stegmann Und Stein, Dominik Hartl, Oliver Gassmann

Drug Discov Today· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The significance of blockbusters in the pharmaceutical industry.
Alexander Schuhmacher, Markus Hinder, Nikolaj Boger, Dominik Hartl, Oliver Gassmann

Nat Rev Drug Discov· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The dominant logic of Big Tech in healthcare and pharma.
Alexander Schuhmacher, Naomi Haefner, Katharina Honsberg, Jörg Goldhahn, Oliver Gassmann

Drug Discov Today· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open innovation: A paradigm shift in pharma R&D?
Alexander Schuhmacher, Oliver Gassmann, Doria Bieniok, Markus Hinder, Dominik Hartl

Drug Discov Today· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic risk identification and assessment using a new risk map in pharmaceutical R&D.
Alexander Schuhmacher, Clara Brieke, Oliver Gassmann, Markus Hinder, Dominik Hartl

Drug Discov Today· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Big Techs and startups in pharmaceutical R&D - A 2020 perspective on artificial intelligence.
Alexander Schuhmacher, Alexander Gatto, Michael Kuss, Oliver Gassmann, Markus Hinder

Drug Discov Today· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
R&D efficiency of leading pharmaceutical companies - A 20-year analysis.
Alexander Schuhmacher, Lucas Wilisch, Michael Kuss, Andreas Kandelbauer, Markus Hinder, Oliver Gassmann

Drug Discov Today· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The present and future of project management in pharmaceutical R&D.
Alexander Schuhmacher, Oliver Gassmann, Markus Hinder, Michael Kuss

Drug Discov Today· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The upside of being a digital pharma player.
Alexander Schuhmacher, Alexander Gatto, Markus Hinder, Michael Kuss, Oliver Gassmann

Drug Discov Today· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Art of Virtualizing Pharma R&D.
Alexander Schuhmacher, Oliver Gassmann, Michael Kuss, Markus Hinder

Drug Discov Today· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?
Alexander Schuhmacher, Oliver Gassmann, Nigel McCracken, Markus Hinder

J Transl Med· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Technologically Reflective Individuals as Enablers of Social Innovation.
Fiona Schweitzer, Christiane Rau, Oliver Gassmann, Ellis van den Hende

J Prod Innov Manage· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Models for open innovation in the pharmaceutical industry.
Alexander Schuhmacher, Paul-Georg Germann, Henning Trill, Oliver Gassmann

Drug Discov Today· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Getting the most out of your IP--patent management along its life cycle.
Martin A Bader, Oliver Gassmann, Nicole Ziegler, Frauke Ruether

Drug Discov Today· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pannexin1 and Pannexin2 channels show quaternary similarities to connexons and different oligomerization numbers from each other.
Cinzia Ambrosi, Oliver Gassmann, Jennifer N Pranskevich, Daniela Boassa, Amy Smock

J Biol Chem· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The M34A mutant of Connexin26 reveals active conductance states in pore-suspending membranes.
Oliver Gassmann, Mohamed Kreir, Cinzia Ambrosi, Jennifer Pranskevich, Atsunori Oshima

J Struct Biol· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis